Literature DB >> 7680908

Outbreak of Pseudomonas cepacia bacteremia in oncology patients.

D A Pegues1, L A Carson, R L Anderson, M J Norgard, T A Argent, W R Jarvis, C H Woernle.   

Abstract

In 1991, an outbreak of Pseudomonas cepacia bacteremia (PCB) occurred among patients at an oncology clinic in Alabama. A case-patient was defined as any patient at Alabama Oncology Hematology Associates (AOHA) who had at least one blood culture positive for P. cepacia from 7 August through 31 October. Fourteen case-patients were identified; all required hospitalization (median duration, 17 days), but none died of PCB. A cohort study assessing risk factors for PCB focused on all patients who had been treated on the 8 days when case-patients had last visited AOHA during the period 7-21 August. Only patients with central venous catheters developed PCB (P < .001). Among patients with central venous catheters, PCB occurred only after visits to AOHA at which the catheters were flushed with heparin solution in the AOHA laboratory rather than in the treatment area (P < .001). P. cepacia was cultured from the only intravenous fluid bag used to prepare heparin flush solution in the laboratory during the interval 7-21 August. All outbreak-associated isolates of P. cepacia had an identical DNA ribotype pattern. These findings emphasize the importance of avoiding multiple use of single-use solutions, especially for high-risk patients with long-term indwelling central venous catheters.

Entities:  

Mesh:

Year:  1993        PMID: 7680908     DOI: 10.1093/clind/16.3.407

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  13 in total

Review 1.  Health service careers for people with cystic fibrosis.

Authors:  Sarah Walters
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

2.  An outbreak of Burkholderia cenocepacia bacteremia in immunocompromised oncology patients.

Authors:  T Mann; D Ben-David; A Zlotkin; D Shachar; N Keller; A Toren; A Nagler; G Smollan; A Barzilai; G Rahav
Journal:  Infection       Date:  2010-04-01       Impact factor: 3.553

Review 3.  Use of ribotyping in epidemiological surveillance of nosocomial outbreaks.

Authors:  E H Bingen; E Denamur; J Elion
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

4.  An epidemic of burkholderia cepacia transmitted between patients with and without cystic fibrosis.

Authors:  A Holmes; R Nolan; R Taylor; R Finley; M Riley; R Z Jiang; S Steinbach; R Goldstein
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

5.  Comparison of rapid, automated ribotyping and DNA macrorestriction analysis of Burkholderia pseudomallei.

Authors:  Timothy J J Inglis; Lyn O'Reilly; Niki Foster; Adele Clair; Judy Sampson
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

Review 6.  Ochrobactrum anthropi bacteremia: report of four cases and short review.

Authors:  W V Kern; M Oethinger; A Kaufhold; E Rozdzinski; R Marre
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

Review 7.  Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation.

Authors:  Alex Horsley; Andrew M Jones; Robert Lord
Journal:  Cochrane Database Syst Rev       Date:  2016-01-20

Review 8.  Agricultural use of Burkholderia (Pseudomonas) cepacia: a threat to human health?

Authors:  A Holmes; J Govan; R Goldstein
Journal:  Emerg Infect Dis       Date:  1998 Apr-Jun       Impact factor: 6.883

9.  Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation.

Authors:  Robert Lord; Andrew M Jones; Alex Horsley
Journal:  Cochrane Database Syst Rev       Date:  2020-04-02

10.  Polyclonal outbreak of bloodstream infections caused by Burkholderia cepacia complex in hematology and bone marrow transplant outpatient units.

Authors:  Icaro Boszczowski; Gladys Villas Boas do Prado; Mirian F Dalben; Roberto C P Telles; Maristela Pinheiro Freire; Thaís Guimarães; Maura S Oliveira; Juliana F Rosa; Robson E Soares; Pedro Enrique Dorlhiac Llacer; Frederico Luiz Dulley; Silvia F Costa; Anna S Levin
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Jan-Feb       Impact factor: 1.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.